Envoy Medical announced that it has finished enrolling all 56 patients in the pivotal clinical trial for its Acclaim cochlear implant, a fully implanted device that replaces the external microphone and speech processor of traditional cochlear implants with an entirely internal, water‑resistant system. The final two implants were performed on March 10, 2026, at the University of Florida, marking the end of the enrollment phase and the beginning of the required 12‑month follow‑up period before a Premarket Approval (PMA) application can be submitted to the FDA.
The completion of enrollment is a critical de‑risking milestone. Envoy’s Acclaim device has already received FDA Breakthrough Device designation, and the company plans to file its PMA in early 2027, with regulatory approval expected in the second half of 2027 or the first half of 2028. Successful approval would unlock a multi‑billion‑dollar market of adults with severe‑to‑profound hearing loss and could transform Envoy’s revenue trajectory from its current $166,000 annual sales to a multi‑hundred‑million‑dollar opportunity.
Envoy’s current revenue base is modest, with $225,000 reported for the twelve months ending December 31, 2024, and $208,000 for the twelve months ending September 30, 2025. Q3 2025 revenue was $42,000, up 25% year‑over‑year. The company’s low sales reflect the early stage of its product portfolio, but the Acclaim trial’s success signals a potential shift toward a larger, more profitable market. The company’s strategic focus is on overcoming reimbursement barriers that limited commercial traction for its earlier Esteem product, which was classified as a hearing aid and faced limited coverage. New Category I CPT codes for fully implanted active middle ear implants became effective in July 2025, providing a clearer reimbursement pathway for Acclaim.
Brent Lucas, Envoy’s CEO, emphasized the milestone’s significance: "We believe today brings us significantly closer to redefining the standard of care for adults with severe to profound hearing loss and potentially growing the overall cochlear implant user base to include those patients who could benefit from a fully implanted solution." He added, "Completing enrollment of a pivotal clinical study that is evaluating a breakthrough‑designated medical device that is expected to bring about generational change to an entire industry is a very big deal."
The company’s experience with Esteem has informed its approach to reimbursement and market access. The new CPT codes, coupled with the Acclaim device’s fully implanted design, position Envoy to secure Category I coding and broader payer acceptance, which are essential for sustainable commercialization. The company’s next steps include completing the 12‑month follow‑up, analyzing data, and preparing the PMA submission, while continuing to engage payers and regulators to secure coverage and reimbursement for the Acclaim cochlear implant.
In summary, Envoy Medical’s enrollment completion marks a pivotal point in its journey toward FDA approval and market entry. The milestone de‑risks the regulatory pathway, supports a potential revenue transformation, and underscores the company’s strategy to overcome reimbursement hurdles and capture a significant share of the growing cochlear implant market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.